secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aligos Therapeutics, Inc. (ALGS)
CIK:        0001799448
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001171843-23-006671
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aligos Q3 net loss $18.0M ($0.41/shr); raises $92M in October PIPE
------------------------------------------------------------------

- Net loss $18.0M ($0.41 per share) vs $18.6M ($0.44) in Q3 2022.
- Cash, equivalents & investments $70.4M at Sep 30, down from $125.8M at Dec 31, 2022.
- Closed $92M private placement in October 2023; projects cash runway through end of 2025.
- FDA cleared IND for NASH THR-β agonist ALG-055009; Phase 2a startup underway.
- Awarded $8.5M NIAID contract to advance coronavirus protease inhibitor ALG-097558.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799448/000117184323006671/0001171843-23-006671-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799448/000117184323006671/f8k_110223.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-006671

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer